Schroder Investment Management Group Raises Stake in Zoetis Inc. $ZTS

Schroder Investment Management Group boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 13.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 162,002 shares of the company’s stock after buying an additional 19,117 shares during the quarter. Schroder Investment Management Group’s holdings in Zoetis were worth $23,704,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Halbert Hargrove Global Advisors LLC boosted its holdings in shares of Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares during the last quarter. Financial Consulate Inc. purchased a new position in shares of Zoetis during the third quarter worth $39,000. SJS Investment Consulting Inc. lifted its position in Zoetis by 1,606.3% during the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after purchasing an additional 257 shares during the period. TruNorth Capital Management LLC acquired a new position in Zoetis during the third quarter valued at $42,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Zoetis in the third quarter valued at $46,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 3.8%

ZTS stock opened at $115.25 on Friday. Zoetis Inc. has a one year low of $115.23 and a one year high of $172.23. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The firm’s fifty day moving average is $125.54 and its 200 day moving average is $132.19. The firm has a market cap of $48.65 billion, a PE ratio of 19.14, a P/E/G ratio of 1.83 and a beta of 0.95.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter in the prior year, the firm posted $1.40 earnings per share. The company’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis’s dividend payout ratio is presently 35.22%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ZTS shares. KeyCorp began coverage on Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating on the stock. UBS Group set a $136.00 price objective on Zoetis in a report on Thursday, January 29th. Piper Sandler restated a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Stifel Nicolaus dropped their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. Finally, BTIG Research reiterated a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Thursday, February 26th. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.